Governments around the world are confronting increasingly common challenges: how to drive economic growth, address demographic changes and productivity pressures, and how to strengthen national ...

In this op-ed, authors argue that Europe will be among the first to confront the central question of how to ensure that ...

On 1 October 2026 in Washington, D.C., IFPMA delivered a statement on the policy on the application of data science in public ...

In this op-ed, authors argue that Europe will be among the first to confront the central question of how to ensure that ...

This op-ed argues that Japan, as the world's first super-aging society, can set a global standard for how prevention protects ...

On 29 September 2026 in Washington, D.C., IFPMA delivered a statement on the strategy for strengthening health emergency and ...

On 25 September 2026 in New York City, IFPMA Director General David Reddy participated in an official panel at the UN ...

100 days after the Ebola Bundibugyo outbreak was declared in the Democratic Republic of the Congo, the global pharmaceutical industry has underlined its track record and commitment to tackling health ...

On 6 July 2026, IFPMA delivered a statement ahead of the seventh meeting of the Intergovernmental Working Group (IGWG 7) on the WHO Pandemic Agreement. The extension of the negotiations provides an ...

R&D is the engine transforming health outcomes for people, economies, and societies. Investment in the research and development (R&D) of innovative medicines and vaccines has driven unprecedented ...

About IFPMA IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ...

Thank you to Africa CDC for convening this important High-Level Meeting at a critical moment. The Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and Uganda, declared in May 2026 by ...